checkAd

STRYKER 864952 - eine der besten Medizintechnikaktien (Seite 46)

eröffnet am 26.07.06 13:50:26 von
neuester Beitrag 07.06.21 19:46:50 von

Beitrag zu dieser Diskussion schreiben


  • 1
  • 46

Begriffe und/oder Benutzer

 

Fragen

 Ja Nein
Avatar
26.07.06 13:54:37
Beitrag Nr. 2 ()
Die Antitrust-Vorladung, die in den letzten Monaten auf dem Kurs von Stryker lastete scheint jetzt langsam ein Ende zu finden...

Stryker CEO: Scope Of DOJ Subpoena 'Has Been Narrowed'

07-20-06 06:43 PM EST
The scope of a recent U.S. Department of Justice antitrust subpoena issued to orthopedic products company Stryker Corp. (SYK) has been "narrowed," Stryker's chief executive said late Thursday.

Stryker, along with multiple rivals in the orthopedics sector, announced last month that it had received a Justice Department subpoena requesting several years worth of documents regarding possible federal criminal and antitrust-law violations.

Speaking on a call with analysts following Stryker's second-quarter earnings release, Stephen P. MacMillan, Stryker's president and chief executive, offered a "modest update" on the scope of the government's probe.

"We're actually pleased to tell you that the scope of this recent subpoena has been narrowed," MacMillan said.

Asked about the matter further, MacMillan said Stryker recently learned that the probe had been narrowed either in terms of product lines or geography. He said he did not know whether this was a Stryker-specific development or an industry development.

Biomet Inc. (BMET), Zimmer Holdings Inc. (ZMH), Smith & Nephew PLC (SNN) and Johnson & Johnson (JNJ) orthopedic unit DePuy Inc. have also reported receiving Justice Department antitrust subpoenas.

On a call with analysts June 28, following Biomet's fiscal fourth-quarter earnings release, Biomet interim Chief Executive Daniel P. Hann called the subpoena Biomet received "very broad," and said the company doesn't know specifically what the investigation is about.

"The subpoena does not signal anything other than an investigation into price and bidding in our industry," Hann said on that call.

Orthopedics companies in early 2005 reported receiving a separate batch of Justice Department subpoenas regarding a probe of consulting or professional- services agreements between companies and orthopedics surgeons. It isn't clear whether that probe is linked to the most recent subpoenas.

Stryker shares were recently up 3%, or $1.30, to $44.50 in after-hours trading, according to Inet. Shares closed down 2.4% at $43.20 during Thursday's regular session.

Stryker reported after the closing bell Thursday second-quarter earnings of $ 213.9 million, or 52 cents a share, up from $177.8 million, or 43 cents a share, in the year-earlier period.

Analysts surveyed by Thomson First Call on average projected earnings of 51 cents a share in the quarter.

- By Jon Kamp; Dow Jones Newswires; 312-750-4129; jon.kamp@dowjones.com
Avatar
26.07.06 13:50:26
Beitrag Nr. 1 ()
Hallo,

ist jemand von Euch in Stryker investiert? Ich bin es seit erd. 1,5 Jahren und für mich eine der "sichersten"Aktien überhaupt, rel konstante wachstumsraten über Jahre und diese auch noch rel hoch um die 20% per anno.
Zudem in einem markt tätig, der viel Phantasie hat. Orthopädieprodukte wie kunstliche Gelenke etc. haben immer mehr Konjunktur bei steigenbdem Wohlstand in der 3. welt und immer älter werdenden menschen. Da spielen die Knochen eben immer öfters nicht mehr mit.
Die aktuelle Ruhepause im Kurs kann als Einstiegschance genutzt werden
Gruss space

Hier die aktuellen Quartalszahlen und der Langfristchart seit 1980:

20.07.2006 22:04
Stryker Operating Results for Quarter Ended June 30, 2006

KALAMAZOO, Mich., July 20 /PRNewswire-FirstCall/ -- Stryker Corporation (Nachrichten) reported operating results for the quarter ended June 30, 2006 as follows:

Second Quarter Highlights * Net sales increased 9.0% (9.4% constant currency) to $1,328 million * Orthopaedic Implant sales increased 6.6% (7.3% constant currency) * MedSurg Equipment sales increased 14.5% (14.4% constant currency) * Net earnings increased 20.3% to $214 million * Diluted net earnings per share increased 20.9% to $.52 * 2006 and 2005 include additional compensation expense of $14.2 million and $10.1 million, respectively, to reflect the expensing of stock option compensation

"We once again delivered on our commitments in the quarter, including strong net earnings growth and the continuing turnaround of our U.S. Orthopaedics division, which reported its third straight quarter of sequentially improved sales growth," commented Stephen P. MacMillan, President and Chief Executive Officer. "We were also particularly pleased by very strong MedSurg growth overseas, which helped offset softer International implant sales growth."

Net sales were $1,327.9 million for the second quarter of 2006, representing a 9.0% increase over net sales of $1,218.6 million in the second quarter of 2005, and $2,648.8 million for the first half of 2006, representing a 9.4% increase over net sales of $2,421.1 million for the first half of 2005. Excluding the impact of foreign currency, net sales increased 9.4% for the second quarter and 10.8% for the first half.

The second quarter and first half results reflect the adoption of Financial Accounting Standards Board (FASB) Statement No. 123R, Share-Based Payment, which requires companies to recognize the cost of stock options as compensation expense. The Company adopted the Statement using the modified- retrospective transition method, under which all prior period amounts have been restated on a consistent basis. As a result of adopting Statement No. 123R, the Company recognized additional compensation expense of $14.2 million and $10.1 million in the second quarter of 2006 and 2005, respectively, and $29.0 million and $19.9 million in the first half of 2006 and 2005, respectively.

Net earnings for the second quarter of 2006 were $213.9 million, representing a 20.3% increase over net earnings of $177.8 million for the second quarter of 2005. Diluted net earnings per share for the second quarter of 2006 increased 20.9% to $.52 compared to $.43 in the second quarter of 2005.

The Company's net earnings for the first half of 2006 were reduced by a $52.7 million charge in the first quarter to write off purchased in-process research and development associated with the acquisition of Sightline Technologies, Ltd. (Sightline).

Excluding the impact of the $52.7 million charge to write off purchased in-process research and development, adjusted net earnings for the first half of 2006 were $414.1 million, representing a 20.2% increase over net earnings of $344.5 million for the first half of 2005, and adjusted diluted net earnings per share for the first half of 2006 were $1.01, representing a 20.2% increase over diluted net earnings per share of $.84 for the first half of 2005.

Reported net earnings for the first half of 2006 were $361.4 million, representing a 4.9% increase over net earnings of $344.5 million in the first half of 2005. Reported diluted net earnings per share for the first half of 2006 increased 4.8% to $.88 compared to $.84 in the first half of 2005.

Sales Analysis

Domestic sales were $864.0 million for the second quarter and $1,731.9 million for the first half of 2006, representing increases of 10.2% and 11.1%, respectively, as a result of higher shipments of Orthopaedic Implants and MedSurg Equipment.

International sales were $463.9 million for the second quarter and $916.9 million for the first half of 2006, representing increases of 6.8% and 6.3%, respectively, as a result of higher shipments of Orthopaedic Implants and MedSurg Equipment. The impact of foreign currency comparisons to the dollar value of international sales was unfavorable by $4.9 million in the second quarter and by $34.8 million in the first half of 2006. Excluding the impact of foreign currency, international sales increased 7.9% in the second quarter and 10.4% in the first half of 2006.

Worldwide sales of Orthopaedic Implants were $771.1 million for the second quarter and $1,534.7 million for the first half of 2006, representing increases of 6.6% and 6.8%, respectively, based on higher shipments of reconstructive (hip, knee and shoulder), trauma, spinal and craniomaxillofacial implant systems; bone cement; and the bone growth factor OP-1. Excluding the impact of foreign currency, sales of Orthopaedic Implants increased 7.3% in the second quarter and 8.9% in the first half of 2006.

Worldwide sales of MedSurg Equipment were $490.7 million for the second quarter and $981.0 million for the first half of 2006, representing increases of 14.5% and 15.0%, respectively, based on higher shipments of surgical equipment; surgical navigation systems; endoscopic, communications and digital imaging systems; as well as patient handling and emergency medical equipment. Excluding the impact of foreign currency, sales of MedSurg Equipment increased 14.4% in the second quarter and 15.5% in the first half of 2006.

Physical Therapy Services revenues were $66.1 million for the second quarter and $133.1 million for the first half of 2006, representing a decrease of 0.5% and an increase of 1.2%, respectively.

Income Tax Rate

The Company's effective income tax rates for the second quarter and first half of 2006 were 27.9% and 31.0%, respectively, as compared to effective income tax rates for the second quarter, first half and year ended December 31, 2005 of 29.2%, 29.3% and 32.6%, respectively. The effective income tax rate for the first half of 2006 reflects the impact of the non-deductibility for income tax purposes of the purchased in-process research and development charge associated with the acquisition of Sightline. The effective income tax rate, excluding the effect of the Sightline acquisition, for the first half of 2006 was reduced from 28.5% to 28.2% in the second quarter of 2006, thereby reducing income tax expense by $1.8 million. The income tax rate reduction results primarily from increased manufacturing in lower tax jurisdictions and a favorable change in U.S. tax legislation enacted during the second quarter. The effective income tax rates for the 2005 periods have been restated to reflect the adoption of FASB Statement No. 123R. The effective income tax rate for the year ended December 31, 2005 also reflects the non-deductibility for income tax purposes of the purchased in-process research and development charge associated with the acquisition of PlasmaSol Corp. as well as the third and fourth quarter 2005 income taxes associated with the repatriation of foreign earnings under the provisions of the American Jobs Creation Act.

Outlook for 2006

The Company's outlook for 2006 continues to be optimistic regarding underlying growth rates in orthopaedic procedures and the Company's broadly based range of products in orthopaedics and other medical specialties, despite the potential for increased pricing pressure on Orthopaedic Implants products in the United States, Japan and certain other foreign markets. The Company projects adjusted diluted net earnings per share for 2006 of $2.02, excluding the impact of the charge to write off purchased in-process research and development associated with the acquisition of Sightline during the first quarter of 2006. The projection represents a 21.0% increase over adjusted restated diluted net earnings per share of $1.67 in 2005.

The financial forecast for 2006 includes a net sales increase in the range of 11% to 13% as a result of growth in shipments of Orthopaedic Implants and MedSurg Equipment and higher revenue from Physical Therapy Services, offset by unfavorable foreign currency exchange rate movements. If foreign currency exchange rates hold near recent levels, the Company does not expect a significant impact on net sales in the third quarter and anticipates an unfavorable impact of 0% to 1% for the full year of 2006. Excluding the effect of foreign currency exchange rates, the Company expects annual net sales growth in the range of 11% to 13% in 2006, which is comparable to the 11% sales growth, excluding the effect of foreign currency exchange rates, reported for the first half of 2006.

Conference Call

As previously announced, the Company will conduct a conference call for financial analysts at 5:00 p.m., Eastern Time, today. To hear the conference call, dial 800/725-9961. A simultaneous webcast of the call may be accessed via the Company's website at http://www.stryker.com/. The call will be archived on this site for 90 days. A recording of the call will also be available from 7:00 p.m., Eastern Time, today until 7:00 p.m. on Saturday, July 22, 2006. To hear this recording dial 800/633-8284 (domestic) or 402/977-9140 (international) and enter the registration number 21279877.

Forward-Looking Statements

This press release contains information that includes or is based on forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties that could cause the Company's actual results to differ materially from those expressed or implied in such statements. Such factors include, but are not limited to: pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for the Company's products; regulatory actions; unanticipated issues arising in connection with clinical studies and eventual United States Food and Drug Administration approval of additional OP-1 applications, the FlexiCore and CerviCore spinal implant products or other new product introductions; integration and other issues that could delay the introduction of the recently acquired Sightline product line; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; changes in economic conditions that adversely affect the level of demand for the Company's products; changes in foreign exchange markets; changes in financial markets; and changes in the competitive environment. Additional information concerning these and other factors are contained in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Stryker Corporation is one of the world's leading medical technology companies with the most broadly based range of products in orthopaedics and a significant presence in other medical specialties. Stryker works with respected medical professionals to help people lead more active and more satisfying lives. The Company's products include implants used in joint replacement, trauma, craniomaxillofacial and spinal surgeries; biologics; surgical, neurologic, ear, nose&throat and interventional pain equipment; endoscopic, surgical navigation, communications and digital imaging systems; as well as patient handling and emergency medical equipment. Stryker also provides outpatient physical therapy services in the United States.

  • 1
  • 46
 DurchsuchenBeitrag schreiben


STRYKER 864952 - eine der besten Medizintechnikaktien